Multiple myeloma is the second most common type of blood cancer, with approximately 450 new cases diagnosed annually in Norway

By Staff Writer

March 29, 2023

A health technology assessment (HTA) of treatment regimens for patients with multiple myeloma in Norway was done. The goals of treatment are to prolong life, achieve a strong response without side effects, and maintain quality of life.

The article discusses the uncertainty surrounding the results of a health economic analysis of treatment regimens for multiple myeloma. The uncertainty is due to reliance on component network meta-analysis and lack of access to patient level data. The methods used to derive underlying survival curves may overestimate treatment costs due to inaccurate accounting for dose reductions during treatment.

The difficulty in drawing clear conclusions about the most effective treatment regimen for patients with refractory or relapsed multiple myeloma is clear. The six triplet combinations mentioned have favourable hazard ratios for overall survival, but there is substantial uncertainty in the evidence. Cost-effectiveness results are also uncertain and need to be viewed in the context of each reference group. Only seven treatments were not dominated by others. Patients with RRMM may lose 12-15 healthy life-years, and there is a high degree of uncertainty in the cost-effectiveness results.

Reference url

Recent Posts

cervical cancer prevention
    

Cervical Cancer Prevention Strategies: Insights from South African

🌍 Did you know South African women living with HIV face a significantly higher risk of cervical cancer?

Our latest article looks into the perspectives of women and their partners regarding innovative cervical cancer prevention strategies, including the acceptability of the intravaginal 5-fluorouracil (5FU) treatment. It highlights the critical role of education and counseling in improving screening uptake and treatment adherence.

Explore how we can enhance cervical health for vulnerable populations!

#SyenzaNews #globalhealth #oncology #HealthcareInnovation

MPA meningioma risk
       

MPA Meningioma Risk: Key Insights and Implications

⚠️ *Are you aware of the new safety warnings surrounding medroxyprogesterone acetate (MPA)?*
The South African Health Products Regulatory Authority (SAHPRA) has clarified crucial information regarding the potential **MPA meningioma risk** associated with prolonged use of this synthetic hormone. While the absolute risk remains low, the implications for patients and healthcare providers are significant.

Dive into the article to understand the updated guidelines and what they mean for clinical practice.

#SyenzaNews #healthcare #oncology #HealthEconomics

MENA generics biologics growth
        

MENA Generics Biologics Healthcare Innovation

💡 *What does the future hold for healthcare in the MENA region?*
The rise of generics and biologics is set to transform healthcare in the Middle East and North Africa, driven by government reforms and an evolving regulatory landscape. Learn how these advancements are making life-saving therapies more accessible and cost-effective for patients across the region.

#SyenzaNews #HealthcareInnovation #pharmaceuticals #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.